Objective : COPD is recognized as systemic inflammation, and statin-use has been reported to be associated with better prognosis in COPD. The objective of this study was to investigate the effects of pitavastatin in hypercholesterolemic patients with COPD. Methods : Twenty six outpatient hypercholesterolemic patients with COPD [forced expiratory volume in 1 second (FEV1) >50%) who provided informed consent were enrolled. Inflammatory markers were measured before and 12 weeks after enrollment. Result and Conclusion : Pitavastatin significantly decreased hs-CRP after 12 weeks (2778.8 ± 4713.9 ng/ ml, 1035.9 ± 1598.7 ng/ml, p = 0.0083). Pitavastatin is suggested to improve systemic inflammation in hypercholesterolemic patients with COPD.
|Number of pages||7|
|Journal||Japanese Journal of Chest Diseases|
|Publication status||Published - 2012|
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine